This site uses cookies in order to function as expected. By continuing, you are agreeing to our cookie policy.
Agree and close

« June 2024 »
Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

HTML Document Article 19 - Handling of biotechnology and distribution of its benefits

Release date 09/02/2006

268-What is the relative priority afforded to implementation of this Article and the associated decisions by your country?
High
Medium  
Low  
269-To what extent are the resources available adequate for meeting the obligations and recommendations made?
Good  
Adequate
Limiting  
Severely limiting  

Further comments on relative priority and on availability of resources

270-Has your country taken measures to provide for the effective participation in biotechnological research activities by those Contracting Parties which provide the genetic resources for such research (19(1))?
no measures
some measures in place  
potential measures under review  
comprehensive measures in place  
If so, are these measures:
Legislation  
Statutory policy and subsidiary legislation  
Policy and admini strative measures 

(270) Together with the partnership activities developed through the Belgian Clearing-House Mechanism, the launch of the Belgian Biosafety Clearing-House could be a first step towards an effective participation of provider Parties.

271-Has your country taken all practicable measures to promote and advance priority access on a fair and equitable basis by Contracting Parties to the results and benefits arising from biotechnologies based upon genetic resources provided by those Contracting Parties (19(2))?
no measures  
some measures in place  
potential measures under review
comprehensive measures in place  

Decision IV/3. Issues related to biosafety and Decision V/1. Work Plan of the Intergovernmental Committee for the Cartagena Protocol on Biosafety

272-Is your country a Contracting Party to the Cartagena Protocol on Biosafety?
not a signatory  
signed, ratification in progress
instrument of ratification deposited  

(272) Belgium is actively participating in the work of the Intergovernmental Committee for the Cartagena Protocol on Biosafety (ICCP), as well as in the various intersessional activities, which are taking place in that framework. For example, the Belgian government has provided the CBD Secretariat with an expert for the meeting of technical experts on the Biosafety Clearing-House which was held in Montreal from 11 to 13 September 2000. Belgium is currently setting up administrative, financial and regulatory measures in order to fulfill its obligations and to prepare for an effective implementation of the Protocol.

Further comments on implementation of this Article

(general) Belgium, as a member state of the European Union, is bound by the European Directives with regard to contained use (219) and deliberate release (220).

logo CBD logo NFP Belgium logo RBINS